The 9MM Atopic Dermatitis Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR % over the projected period. And by 2033, the market is expected to touch USD XX Million.
Market Outline:
- Atopic dermatitis is a persistent, pruritic, provocative skin illness that happens most often in youngsters yet additionally influences grown-ups. There are most common symptoms of AD includes dry, scaly patches of skin, open, crusted, or weeping sores, skin flushing, thickened, discoloured skin and itching. AD ranks 15th among all non-fatal diseases with regard to disability-adjusted life years, and first among all skin diseases (based on Global Burden of Disease (GBD) estimates), with the main burden in children.
Disease Burden Analysis:
- Around the world nearly 224 million individuals were living with atopic dermatitis in 2023. Approximately 43.7 million are matured
- The event of atopic dermatitis (Advancement) in everyone is represented to go from 10 to 24% (15 to 25% in youths and 10 to 15% in adults in Western countries).
Report Insights:
- More than 250 clinical trials, United States is the dominated region
- Huge unmet need exists
- 30-40 molecules might witness the market by 2038 during forecast period
- CSP Analytics Solutions provided the clinical mapping of key pipeline molecules
The 9MM Atopic Dermatitis Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR % over the projected period. And by 2033, the market is expected to touch USD XX Million.
Market Segmentation Analysis by:
- By Drug Type:
- Corticosteroids
- Antihistamines
- Phosphodiesterase Inhibitors
- Oral JAK inhibitors
- Others
- By Formulation:
- Topical
- Creams
- Lotions
- Ointments
- Others
- Oral
- Injectable
- By Therapy:
- OTC Medication
- Prescription Medications
- Wet Wrap Therapy
- Phototherapy
- Others
- By Severity:
- By End User:
Market Enablers: Explored in report
- Surging Prevalence of Atopic Dermatitis Across Region
- Growing Clinical Trial Activities
- Huge Market Unmet Need
- Favourable Drug Reimbursement Policies
Market Challenges: Explored in report
- Lack of Efficacious Treatment Option
- Cost of Treatment
- Underdiagnoses in Emerging Market
Regional Outlook:
Report has fragmented the total market in five regions such as US, 5-Europe, China, Japan, India and RoW (Rest of world).
Each mapped region has been examined at granular level based on certain parameters:
- United States Atopic Dermatitis Treatment Market
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- 5-Europe Atopic Dermatitis Treatment Market
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- China Atopic Dermatitis Treatment Market
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- India Atopic Dermatitis Treatment Market
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- Japan Atopic Dermatitis Treatment Market
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
- Rest of the World Atopic Dermatitis Treatment Market
- Market Size and Forecast Model 2023-2033
- Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
- Drug Share Analysis (%)
- Prescription (Rx) Generated (000' Units)
- Reimbursement of Drugs
- Assessment of Demand and Market Penetration
- Market Unmet Need Analysis
- Pipeline Drugs in the Region
- Key Players in the Market and their Market share (%)
Competitive Landscape:
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Companies Profile:
- Pfizer
- Sanofi
- Regeneron
- Eli Lilly
- Teva Pharmaceuticals
- Bristol-Myers Squibb
- Suzhou Connect Biopharmaceuticals, Ltd
- Arcutis Biotherapeutics
- LEO Pharma Inc.
- Jiangsu vcare pharmaceutical technology co., LTD
- GlaxoSmithKline
- Almirall, S.A.
- Novartis Pharmaceuticals
- Akesobio Australia Pty Ltd
- Allakos Inc.
- Shanghai Mabgeek Biotech.Co.Ltd.
- RAPT Therapeutics, Inc.
- Evelo Biosciences, Inc.
- Q32 Bio Inc.
- ASLAN Pharmaceuticals
- Aldeyra Therapeutics, Inc.
- Evelo Biosciences, Inc.
- Ribon Therapeutics, Inc.
- Tavotek Biotherapeutics
- Others
Pipeline Assets Investigated in the Report:
- VC005
- ADX-914
- LAS 41002
- GW842470X
- EDP1815
- TAVO101
- MG-K10
- RPT193
- RBN-3143
- Others
